Oncotarget

Research Papers:

Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth

Audrey Vincent, Seung-Mo Hong, Chaoxin Hu, Noriyuki Omura, Angela Young, Haeryoung Kim, Jun Yu, Spencer Knight, Michael Ayars, Margaret Griffith, Isabelle Van Seuningen, Anirban Maitra and Michael Goggins _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:2575-2587. https://doi.org/10.18632/oncotarget.1842

Metrics: PDF 2765 views  |   HTML 3092 views  |   ?  


Abstract

Audrey Vincent1, Seung-Mo Hong1, Chaoxin Hu1, Noriyuki Omura1, Angela Young1, Haeryoung Kim1, Jun Yu1, Spencer Knight1, Michael Ayars1, Margaret Griffith1, Isabelle Van Seuningen4,5,6, Anirban Maitra1 and Michael Goggins1,2,3

1 Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Johns Hopkins University, Baltimore, MD, USA

2 Department of Oncology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Johns Hopkins University, Baltimore, MD, USA

3 Department of Medicine, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Johns Hopkins University, Baltimore, MD, USA

4 Inserm, UMR837, Jean-Pierre Aubert Research Center, Lille Cedex, France,

5 Université Lille Nord de France, Lille Cedex, France,

6 Centre Hospitalier Régional et Universitaire de Lille, Lille Cedex, France.

Correspondence:

Michael Goggins, email:

Keywords: EYA2, pancreatic cancer, epigenetic

Received: February 14, 2014 Accepted: March 20, 2014 Published: March 22, 2014

Abstract

To identify potentially important genes dysregulated in pancreatic cancer, we analyzed genome-wide transcriptional analysis of pancreatic cancers and normal pancreatic duct samples and identified the transcriptional coactivator, EYA2 (Drosophila Eyes Absent Homologue-2) as silenced in the majority of pancreatic cancers. We investigated the role of epigenetic mechanisms of EYA2 gene silencing in pancreatic cancers, performed in vitro and in vivo proliferation and migration assays to assess the effect of EYA2 silencing on tumor cell growth and metastasis formation, and expression analysis to identify genes transcriptionally regulated by EYA2. We found loss of tumoral Eya2 expression in 63% of pancreatic cancers (120/189 cases). Silencing of EYA2 expression in pancreatic cancer cell lines correlated with promoter methylation and histone deacetylation and was reversible with DNA methyltransferase and HDAC inhibitors. EYA2 knockdown in pancreatic cancer cell lines increased cell proliferation. Compared to parental pancreatic cancer cells, pancreatic cancers stably-expressing EYA2 grew more slowly and had fewer metastases in orthotopic models. The transcriptional changes after stable expression of EYA2 in pancreatic cancer cells included induction of genes in the TGFbeta pathway. Epigenetic silencing of EYA2 is a common event in pancreatic cancers and stable expression EYA2 limits the growth and metastases of pancreatic adenocarcinoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1842